Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Exelixis, Inc. presented at the Stifel 2026 Targeted Oncology Virtual Forum, highlighting their ongoing development efforts. The focus was on their product Zanza, which is being evaluated for various tumor types. A key upcoming milestone is the December PDUFA date for third-line colorectal cancer based on the STELLAR-303 data.
- ▪Exelixis, Inc. participated in the Stifel 2026 Targeted Oncology Virtual Forum.
- ▪The company is focusing on their product Zanza for multiple tumor types.
- ▪A significant PDUFA date is approaching in December for third-line colorectal cancer.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907198-exelixis-inc-exel-presents-at-stifel-2026-targeted-oncology-virtual-forum-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
